Fused-Cyclic Pyrazolone Formamides for Selective AXL Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current AXL kinase inhibitors lack selectivity, leading to non-specific inhibition of other kinases, which complicates treatment efficacy and contributes to drug resistance in tumors.
Innovation Solution
Development of a class of fused-cyclic pyrazolone formamide compounds that selectively target AXL kinase, providing a novel structure with specific inhibitory properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule kinase inhibitors are used to target AXL, then anti-tumor effectiveness is improved, but selectivity deteriorates causing non-specific inhibition of other kinases
Solution Approach 1:
The patent applies local quality by introducing specific substituent patterns at defined positions of the pyrazolone core structure. Different substituents (R1-R6) are placed at specific locations to optimize binding to AXL kinase while avoiding off-target effects, achieving both effectiveness and selectivity through localized structural modifications
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular weight, lipophilicity, and hydrogen bonding capacity through different substituent combinations. These parameter optimizations enable the compound to achieve nanomolar potency against AXL while maintaining selectivity over other kinases
2Adaptability or versatility
If non-selective kinase inhibitors are used, then broad anti-tumor coverage is achieved, but drug resistance develops due to compensatory pathways
Solution Approach 1:
The patent extracts and targets the specific AXL kinase pathway responsible for drug resistance in EGFR-inhibited tumors. By isolating AXL as the primary target rather than using broad-spectrum inhibitors, the compound overcomes resistance mechanisms while maintaining anti-tumor effectiveness in AXL-driven malignancies
3Reliability
If existing AXL inhibitors like BGB324 are used, then AXL inhibition is achieved, but cross-inhibition of related kinases (Mer, Tyro-3, ABL) occurs
Solution Approach 1:
The patent achieves kinase selectivity through local quality by positioning specific substituents (particularly at R3, R4, and R5 positions) that create steric and electronic differences distinguishing AXL from related kinases. This localized structural differentiation prevents cross-inhibition while maintaining AXL potency
Solution Approach 2:
The patent applies asymmetry by introducing chiral centers and asymmetric substituent patterns that exploit the asymmetric binding pocket of AXL kinase. This asymmetric design enhances selectivity over symmetric or differently shaped kinase binding sites, reducing off-target effects
Data Source
AI summary
Provided are a class of fused-cyclic pyrazolone formamide compounds and a preparation method therefor, a pharmaceutical composition and the use thereof. Specifically, provided is a compound having the structure as shown in formula (I) (with each group defined in the description). The compound can be used as an AXL inhibitor in the preparation of a pharmaceutical composition for treating tumors.